The AJMC® Precision Medicine in Oncology compendium is a comprehensive resource for clinical news and expert insights for molecular profiling of tumors.
Dr Michael Korn Discusses Precision Medicine Progress in Various Cancers
November 29th 2020There are certain diseases, like lung cancer, that are leading the way in precision medicine and where broad molecular testing is recommended, said W. Michael Korn, MD, of University of California, San Francisco, and Caris Life Sciences.
Watch
Researchers Develop AI Model to Predict ICI Response in Advanced Melanoma
November 20th 2020Results of the artificial intelligence (AI) model were consistent no matter which immune checkpoint inhibitor (ICI) therapy patients received, suggesting that some biomarkers are not necessarily specific to the checkpoint target.
Read More
Moving Beyond Precision Oncology to “Precision Prevention” in Oncology Practices
November 11th 2020In a pair of sessions at the Quality Cancer Care Alliance Virtual Fall Leadership Summit, speakers discussed the promise of precision medicine for not only informing individuals’ cancer treatment decisions but also identifying individuals at high risk before disease develops.
Read More
Broad Testing for Multiple Genes Benefits Patients With Cancer, Relatives
October 30th 2020Researchers conducting broad next-generation sequencing discovered more actionable variants in patients and families than they would have otherwise; they did so by using a universal approach, rather than sticking with clinical guidelines.
Read More
Dr Blythe Adamson: Checkpoint Inhibitor Approval Linked to Uptick in Systemic End-of-Life Care
October 8th 2020Blythe Adamson, PhD, MPH, of Flatiron Health, discusses study results she presented at the annual American Society of Clinical Oncology meeting on the use of immune checkpoint inhibitors in end-of-life care
Watch
FDA Clears Targeted Therapy, Diagnostic for Metastatic RET Fusion-Positive NSCLC
September 9th 2020Pralsetinib (Gavreto), developed by Blueprint Medicines, received accelerated approval. Thermo Fisher Scientific's Oncomine Dx Target Test received premarket approval as a companion diagnostic to identify patients who are candidates for the once-daily oral RET-targeted therapy.
Read More